open access

Vol 79, No 7 (2008)
ARTICLES
Get Citation

The correlation of a positive DNA HPV HR test and genotyping human papilloma viruses with the presence of CIN, in women with cytologic evidence of ASC-US and LSIL

Marek Spaczyński, Witold Kędzia, Dominik Pruski, Agata Józefiak, Małgorzata Szczepańska, Maciej Będziński
Ginekol Pol 2008;79(7).

open access

Vol 79, No 7 (2008)
ARTICLES

Abstract

Abstract Introduction: Diagnostic algorithm for women with ASC-US presumes the possibility of performing molecular test for DNA HPV HR, colposcopy or repeated cytology. The latest suggestions of diagnostic algorithm modification in case of cytologic interpretation of LSIL, are based on trial of performing molecular DNA HPV HR test and/or genotyping human papilloma viruses with the special indication for type 16. These suggestions presume performing colposcopy in women with DNA HPV HR or DNA HPV 16 (+). Material and method: Triage study included 67 women with ASC-US and 48 women with LSIL. All 115 women were examined with the use of molecular test Amplicor HPV Roche Diagnostics, which identifies the presence of any out of 13 oncogenic DNA HPV types. 14 women with LSIL DNA HPV HR (+) interpretation, were additionally tested for identification of HPV genotypes presence. In all women with cytologic evidence of ASC-US and LSIL, a colposcopic examination was further performed. Results: Among 67 examined women with ASC-US interpretation, 31 had a (+) test for the presence of any out of 13 HPV HR, while in 12 patients, the result of pathomorphological examination confirmed at least the presence of CIN 1. In none of 36 patients with ASC-US , DNA HPV HR (-) interpretation, the presence of CIN was confirmed. For 29 women with LSIL, (+) test result for any out of 13 HPV HR was obtained. In 11 patients out of this group, at least the presence of CIN 1 was recognized. Following 19 women with LSIL had a negative test result for DNA HPV HR. In none of the patients with DNA HPV HR (-), the presence of CIN was confirmed. DNA HPV 16 was recognized in 5/9 patients with LSIL, without CIN. In 5 patients with LSIL, who underwent HPV genotyping, and were diagnosed for CIN, 4/5 were DNA HPV 16 (+). The most common HPV types in women with LSIL and the presence of CIN include; HPV 16 and HPV 31. Conclusions: 1. Negative DNA HPV HR result, identifies precisely women with ASC-US and LSIL, without CIN. 2. Genotyping exclusively DNA HPV 16 in women with LSIL, in order to detect CIN is characterized by lower sensitivity and specificity in comparison with universal test for 13 oncogenic HPV types.

Abstract

Abstract Introduction: Diagnostic algorithm for women with ASC-US presumes the possibility of performing molecular test for DNA HPV HR, colposcopy or repeated cytology. The latest suggestions of diagnostic algorithm modification in case of cytologic interpretation of LSIL, are based on trial of performing molecular DNA HPV HR test and/or genotyping human papilloma viruses with the special indication for type 16. These suggestions presume performing colposcopy in women with DNA HPV HR or DNA HPV 16 (+). Material and method: Triage study included 67 women with ASC-US and 48 women with LSIL. All 115 women were examined with the use of molecular test Amplicor HPV Roche Diagnostics, which identifies the presence of any out of 13 oncogenic DNA HPV types. 14 women with LSIL DNA HPV HR (+) interpretation, were additionally tested for identification of HPV genotypes presence. In all women with cytologic evidence of ASC-US and LSIL, a colposcopic examination was further performed. Results: Among 67 examined women with ASC-US interpretation, 31 had a (+) test for the presence of any out of 13 HPV HR, while in 12 patients, the result of pathomorphological examination confirmed at least the presence of CIN 1. In none of 36 patients with ASC-US , DNA HPV HR (-) interpretation, the presence of CIN was confirmed. For 29 women with LSIL, (+) test result for any out of 13 HPV HR was obtained. In 11 patients out of this group, at least the presence of CIN 1 was recognized. Following 19 women with LSIL had a negative test result for DNA HPV HR. In none of the patients with DNA HPV HR (-), the presence of CIN was confirmed. DNA HPV 16 was recognized in 5/9 patients with LSIL, without CIN. In 5 patients with LSIL, who underwent HPV genotyping, and were diagnosed for CIN, 4/5 were DNA HPV 16 (+). The most common HPV types in women with LSIL and the presence of CIN include; HPV 16 and HPV 31. Conclusions: 1. Negative DNA HPV HR result, identifies precisely women with ASC-US and LSIL, without CIN. 2. Genotyping exclusively DNA HPV 16 in women with LSIL, in order to detect CIN is characterized by lower sensitivity and specificity in comparison with universal test for 13 oncogenic HPV types.
Get Citation

Keywords

LSIL low sqamous intraepithelial lesion, ASC-US atypical squamous cells of undetermined significance, molecular test, human papilloma virus

About this article
Title

The correlation of a positive DNA HPV HR test and genotyping human papilloma viruses with the presence of CIN, in women with cytologic evidence of ASC-US and LSIL

Journal

Ginekologia Polska

Issue

Vol 79, No 7 (2008)

Bibliographic record

Ginekol Pol 2008;79(7).

Keywords

LSIL low sqamous intraepithelial lesion
ASC-US atypical squamous cells of undetermined significance
molecular test
human papilloma virus

Authors

Marek Spaczyński
Witold Kędzia
Dominik Pruski
Agata Józefiak
Małgorzata Szczepańska
Maciej Będziński

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl